DALLAS, Sept. 17 (UPI) -- Men treated for prostate cancer -- either with surgery or radiation -- could benefit from taking aspirin regularly, U.S. researchers suggest.

First author Dr. Kevin Choe of the University of Texas Southwestern Medical Center in Dallas said preclinical studies showed aspirin and other anti-coagulation medications -- warfarin, clopidogrel, enoxaparin, and/or aspirin -- might inhibit cancer growth and metastasis, but clinical data had been limited previously.

The current study looked at almost 6,000 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database of men who had prostate cancer treated.

About 2,200 of the men involved -- 37 percent -- were receiving anticoagulants. The risk of death from prostate cancer was compared between those taking anti-coagulants and those who were not.

The study, published in the Journal of Clinical Oncology, demonstrated 10-year mortality from prostate cancer was 3 percent in the group taking anti-coagulants, compared to the 8 percent who didn‘t take anticoagulants. The risk of cancer recurrence and bone metastasis also were significantly lower, the study said.

However, further analysis suggested that this benefit was primarily derived from taking aspirin, as opposed to other types of anti-coagulants, Choe said.

“The results from this study suggest that aspirin prevents the growth of tumor cells in prostate cancer, especially in high-risk prostate cancer, for which we do not have a very good treatment currently,” Choe said in a statement.

<관련 한글 기사>

전립선암? ’이걸’ 먹으면 효과본다

전립선암 때문에 수술이나 방사능 치료를 받아본 남성들은 아스피린을 정기적으로 복용하면 효과를 볼 수 있다는 연구 결과가 나왔다.

미국 달라스의 케빈 최 박사의 임상전 연구에 따르면 아스피린과 다른 항응고제들은 암의 성장과 전이를 방해할 가능성이 있다고 한다.

최 박사는 6000명의 전립선암 환자를 대상으로 연구를 진행했다. 그 중 2,200명(37퍼센트)의 남성이 항응고제를 복용했고 그렇지 않은 그룹과 비교한 결과 항응고제를 복용한 그룹의 향후 10년간 사망률이 3퍼센트로 복용을 하지 않은 그룹의 8퍼센트 사망율보다 낮았다.

암 재발율과 골 전이율도 항응고제를 복용한 그룹에서 현저히 낮았다.

최 박사는 특히 다른 항응고제보다도 아스피린을 주로 복용했기 때문에 이런 결과가 나왔다고 말했다.

(코리아헤럴드)